Capmatinib

also known as INC280 · CAPMATINIB (INCB28060) · Capmatinib dihydrochloride monohydrate · CAPMATINIB HYDROCHLORIDE · Capmatinib hydrochloride hydrate · Capmatinib hydrochloride monohydrate · INCB 28060 · INCB-28060 FREE BASE · +7 more

Small molecule targets MET via inhibition

Developed for: non-small cell lung carcinoma · hepatocellular carcinoma · cancer · colorectal cancer · hematopoietic and lymphoid cell neoplasm · melanoma · soft tissue sarcoma · breast cancer
+18 more
· childhood malignant neoplasm · cutaneous melanoma · esophageal adenocarcinoma · gastric adenocarcinoma · gastric cancer · glioma · head and neck squamous cell carcinoma · high grade astrocytic tumor · kidney cancer · lung adenocarcinoma · lung cancer · metastatic malignant neoplasm · metastatic neoplasm · neoplasm · neuroblastoma · squamous cell lung carcinoma · triple-negative breast carcinoma · glioblastoma
Investigated by: Novartis Pharmaceuticals · Novartis · Cancer Research UK · National Cancer Institute (NCI) · Royal Marsden NHS Foundation Trust · University of Birmingham
+44 more
· University of Manchester · Asan Medical Center · Assistance Publique - Hôpitaux de Paris · Celcuity Inc · Collin Blakely · EUCLID Clinical Trial Platform · Fight Kids Cancer · Fondation ARC · French Alternative Energies and Atomic Energy Commission · French National Institute of Health and Medical Research · Gustave Roussy, Cancer Campus, Grand Paris · Haukeland University Hospital · Helse Fonna · Helse Forde · Helse Møre og Romsdal HF · Helse Nord-Trøndelag HF · Helse Stavanger HF · Hoffmann-La Roche · Hospital of Southern Norway Trust · Innlandet Hospital Trust · Institut Bergonié · Janssen Research & Development, LLC · Lovisenberg Diakonale Hospital · M.D. Anderson Cancer Center · Massachusetts General Hospital · National Cancer Institute, France · Nordland Hospital · Oslo University Hospital · Ostfold Hospital Trust · Pfizer · Plateforme labellisée Inca - Hôpital Européen Georges Pompidou, Paris · Plateforme labellisée Inca - Institut Bergonié, Bordeaux · Puma Biotechnology, Inc. · SCRI Development Innovations, LLC · St. Olavs Hospital · Sun Yat-sen University · Sykehuset Telemark · The Hospital of Vestfold · Timothy Burns, MD, PHD · University Hospital of North Norway · University Hospital, Akershus · University of California, Davis · University of California, San Francisco · Vestre Viken Hospital Trust

Regulatory milestones approvals, filings & regulatory actions · 5 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Filed non-small cell lung carcinoma 2 milestones
Filed	Japan (PMDA)	—	non-small cell lung carcinoma	2020-05-29	“Novartis Japan K.K. has submitted the regulatory application of capmatinib to the MHLW.” chugai-pharm.co.jp ↗
Filed	US (FDA)	—	non-small cell lung carcinoma	—	“Capmatinib (INC280) was submitted to FDA with breakthrough therapy designation for NSCLC.” novartis.com ↗
Approved Indication not stated 3 milestones
Label expansion	US (FDA)	TABRECTA	—	2022-08-10	fda.gov ↗
Approved	EU (EMA)	Tabrecta	—	2022-06-20	europa.eu ↗
Approved	US (FDA)	TABRECTA	—	2020-05-06	fda.gov ↗

Trials 49

today

US approved 2020

EU approved 2022

NCT06988475 · Ph 2/3 NCT06054191 · Ph 2 NCT05567055 · Ph 2 NCT05722886 · Ph 2/3 NCT05488314 · Ph 1/2 NCT05110196 · Ph 4 NCT05243641 · Ph 1/2 NCT05435846 · Ph 1 NCT04926831 · Ph 2 NCT05135845 · Ph 2 NCT04816214 · Ph 3 NCT04677595 · Ph 2 NCT04817956 · Ph 2 NCT04460729 · Ph 2 NCT04427072 · Ph 3 NCT04323436 · Ph 2 NCT04139317 · Ph 2 NCT03784014 · Ph 3 NCT03742349 · Ph 1 NCT03647488 · Ph 2 NCT03693339 · Ph 2 NCT03484923 · Ph 2 NCT03240393 · Ph 2 NCT03333343 · Ph 1 NCT03040973 · Ph 2 NCT01964235 · Ph 2 NCT02925104 · Ph 1 NCT02813135 · Ph 1/2 NCT02795429 · Ph 1/2 NCT02750215 · Ph 2 NCT02520752 · Ph 1 NCT02626234 · Ph 1 NCT02468661 · Ph 1 NCT02386826 · Ph 1 NCT02474537 · Ph 1 NCT02414139 · Ph 2 NCT02587650 · Ph 2 NCT02323126 · Ph 2 NCT02276027 · Ph 2 NCT02335944 · Ph 1/2 NCT02205398 · Ph 1 NCT02159066 · Ph 2 NCT02019693 · Ph 2 NCT01870726 · Ph 1/2 NCT01911507 · Ph 1 NCT01737827 · Ph 2 NCT01610336 · Ph 2 NCT01324479 · Ph 1 NCT01546428 · Ph 1

201220132014201520162017201820192020202120222023202420252026202720282029203020312032203320342035203620372038203920402041

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 113 trials
Phase 1	NCT05435846	Aug 2022 → Nov 2023	non-small cell lung carcinoma	Collin Blakely	Terminated	No outcome recorded Stop: Enrollment
Phase 1	NCT03742349	Jan 2019 → Feb 2023	triple-negative breast carcinoma	Novartis Pharmaceuticals	Terminated	No outcome recorded Stop: Business
Phase 1	NCT03333343	Jan 2018 → Oct 2026 expected	non-small cell lung carcinoma	Novartis Pharmaceuticals	Active not recruiting	No outcome recorded
Phase 1	NCT02925104	Dec 2016 → May 2018	neoplasm	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT02520752	Dec 2015 → Jan 2017	—	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT02626234	Dec 2015 → Feb 2017	—	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT02468661	Sep 2015 → Nov 2017	non-small cell lung carcinoma	Novartis Pharmaceuticals	Terminated	No outcome recorded Stop: Enrollment
Phase 1	NCT02386826	Sep 2015 → Jul 2021	colorectal cancer, gliosarcoma, renal cell carcinoma	SCRI Development Innovations, LLC	Completed	No outcome recorded
Phase 1	NCT02474537	Jun 2015 → Aug 2017	—	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT02205398	Jul 2014 → Jan 2017	colorectal cancer, head and neck squamous cell carcinoma	Novartis Pharmaceuticals	Terminated	No outcome recorded
Phase 1	NCT01911507	Aug 2013 → Aug 2020	non-small cell lung carcinoma	University of California, Davis	Completed	No outcome recorded
Phase 1	NCT01324479	Feb 2012 → Jul 2017	cancer	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT01546428	Feb 2012 → Jan 2016	—	Novartis Pharmaceuticals	Completed	No outcome recorded

Phase 1/26 trials · 1 missed
Phase 1/2	NCT05488314	Dec 2022 → Apr 2027 expected	non-small cell lung carcinoma	Janssen Research & Development, LLC	Active not recruiting	No outcome recorded
Phase 1/2	NCT05243641	Aug 2022 → Nov 2024	breast cancer, metastatic neoplasm	M.D. Anderson Cancer Center	Terminated	No outcome recorded
Phase 1/2	NCT02813135	Aug 2016 → Feb 2031 expected	childhood malignant neoplasm	Gustave Roussy, Cancer Campus, Grand Paris	Recruiting	No outcome recorded
Phase 1/2	NCT02795429	Jun 2016 → Jun 2021	hepatocellular carcinoma	Novartis Pharmaceuticals	Completed	Missed primary
Phase 1/2	NCT02335944	Jan 2015 → Nov 2020	non-small cell lung carcinoma	Novartis Pharmaceuticals	Terminated	No outcome recorded
Phase 1/2	NCT01870726	Jan 2014 → Dec 2016	high grade astrocytic tumor	Novartis Pharmaceuticals	Terminated	No outcome recorded
Phase 224 trials · 1 met primary
Phase 2	NCT06054191	Feb 2024 → Mar 2025 overdue	non-small cell lung carcinoma	Sun Yat-sen University	Not yet recruiting	No outcome recorded
Phase 2	NCT05567055	Oct 2023 → Sep 2026	non-small cell lung carcinoma	Timothy Burns, MD, PHD	Withdrawn	No outcome recorded Stop: Enrollment
Phase 2	NCT04926831	Aug 2022 → Mar 2024	non-small cell lung carcinoma	Novartis Pharmaceuticals	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT05135845	Mar 2022 → Apr 2023	esophageal adenocarcinoma, gastric adenocarcinoma	Assistance Publique - Hôpitaux de Paris	Suspended	No outcome recorded Stop: Business
Phase 2	NCT04677595	May 2021 → Oct 2023	non-small cell lung carcinoma	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT04817956	Apr 2021 → Mar 2040 expected	metastatic malignant neoplasm	Oslo University Hospital	Recruiting	No outcome recorded
Phase 2	NCT04460729	Nov 2020 → Nov 2023	non-small cell lung carcinoma	Novartis Pharmaceuticals	Withdrawn	No outcome recorded
Phase 2	NCT04323436	Aug 2020 → Dec 2022	non-small cell lung carcinoma	Novartis Pharmaceuticals	Terminated	No outcome recorded Stop: Business
Phase 2	NCT04139317	Jan 2020 → Jan 2022	non-small cell lung carcinoma	Novartis Pharmaceuticals	Terminated	No outcome recorded Stop: Business
Phase 2	NCT03647488	Dec 2018 → Sep 2020	non-small cell lung carcinoma	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT03693339	Oct 2018 → Jun 2020	lung cancer	Asan Medical Center	Unknown	No outcome recorded
Phase 2	NCT03484923	Sep 2018 → Dec 2022	melanoma	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT03240393	Jul 2018 → Oct 2021	non-small cell lung carcinoma	Novartis Pharmaceuticals	Withdrawn	No outcome recorded
Phase 2	NCT03040973	Jul 2017 → Jul 2027 expected	—	Novartis Pharmaceuticals	Active not recruiting	No outcome recorded
Phase 2	NCT01964235	Dec 2016 → Jul 2019	hepatocellular carcinoma	Novartis Pharmaceuticals	Withdrawn	No outcome recorded
Phase 2	NCT02750215	May 2016 → May 2021	non-small cell lung carcinoma	Massachusetts General Hospital	Completed	No outcome recorded
Phase 2	NCT02414139	Jun 2015 → Apr 2023	non-small cell lung carcinoma	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT02587650	Mar 2015 → Jul 2018	NTRK fusion positive cancer, RET fusion positive cancer, cutaneous melanoma	University of California, San Francisco	Terminated	No outcome recorded Stop: Business
Phase 2	NCT02323126	Feb 2015 → Sep 2019	non-small cell lung carcinoma	Novartis Pharmaceuticals	Terminated	Met primary Stop: Enrollment
Phase 2	NCT02276027	Jan 2015 → Oct 2019	lung adenocarcinoma, squamous cell lung carcinoma	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT02159066	Jul 2014 → Jan 2023	melanoma	Pfizer	Completed	No outcome recorded
Phase 2	NCT02019693	Jan 2014 → Dec 2021	kidney cancer	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT01737827	Mar 2013 → Apr 2023	hepatocellular carcinoma	Novartis Pharmaceuticals	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT01610336	Apr 2012 → Jun 2016	non-small cell lung carcinoma	Novartis Pharmaceuticals	Completed	No outcome recorded

Phase 2/32 trials
Phase 2/3	NCT06988475	Nov 2024 → Oct 2029 expected	gastric cancer, glioma, hematopoietic and lymphoid cell neoplasm, neuroblastoma +1	Cancer Research UK	Recruiting	No outcome recorded
Phase 2/3	NCT05722886	Mar 2023 → Oct 2029 expected	cancer, hematopoietic and lymphoid cell neoplasm	Cancer Research UK	Recruiting	No outcome recorded
Phase 33 trials
Phase 3	NCT04816214	Sep 2021 → Dec 2022	non-small cell lung carcinoma	Novartis Pharmaceuticals	Terminated	No outcome recorded Stop: Business
Phase 3	NCT04427072	Sep 2020 → Feb 2023	non-small cell lung carcinoma	Novartis Pharmaceuticals	Terminated	No outcome recorded
Phase 3	NCT03784014	Oct 2019 → Dec 2023	soft tissue sarcoma	French National Institute of Health and Medical Research	Completed	No outcome recorded
Phase 41 trial
Phase 4	NCT05110196	Sep 2022 → Aug 2025	non-small cell lung carcinoma	Novartis Pharmaceuticals	Completed	No outcome recorded
Comparator or background therapy2 trials
Phase 2	NCT05642572 Background	May 2023 → Jun 2027 expected	non-small cell lung carcinoma	SWOG Cancer Research Network	Recruiting	No outcome recorded
—	NCT04741789 Background	—	non-small cell lung carcinoma	Novartis Pharmaceuticals	No longer available	No outcome recorded

News releases announcing trial results or a regulatory action · 20

Date	Issuer	Release
2024-05-23	Janssen Research & Development, LLC	Results Johnson & Johnson advances leadership in oncology innovation with more than 75 clinical study and real-world presentations at ASCO and EHA jnj.com ↗ Amivantamab plus capmatinib in advanced NSCLC harboring MET alterations: Identification of the recommended Phase 2 combination dose and preliminary dose-escalation results from the Phase 1/2 METalmark study
2022-06-22	Novartis Pharmaceuticals	Regulatory Novartis receives European Commission approval for Tabrecta® for the treatment of METex14 skipping advanced non-small cell lung cancer novartis.com ↗
2022-04-22	Novartis Pharmaceuticals	Regulatory Novartis receives positive CHMP opinion for Tabrecta® for patients with METex14 advanced non-small cell lung cancer novartis.com ↗
2022-04-22	Incyte Corporation	Regulatory Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta®) for the Treatment of METex14 Advanced Non-Small Cell Lung Cancer incyte.com ↗
2021-06-04	Novartis Pharmaceuticals	Results Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC novartis.com ↗ Tabrecta ® (capmatinib) showed a median overall survival (OS) of 20.8 months in treatment-naïve patients and 13.6 months in previously-treated patients in first published mature data
2020-09-02	Novartis Pharmaceuticals	Results Novartis announces NEJM publication of pivotal study of Tabrecta™ in patients with METex14 metastatic non-small cell lung cancer novartis.com ↗ Positive duration of response (DOR) was also observed 1 .
2020-09-02	Incyte Corporation	Results Incyte Announces Pivotal GEOMETRY mono-1 Study Results of Capmatinib (Tabrecta™) in Patients with METex14 Metastatic Non-Small Cell Lung Cancer Published in NEJM incyte.com ↗
2020-06-29	Novartis Pharmaceuticals	Regulatory Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options novartis.com ↗
2020-06-29	Novartis Pharmaceuticals	Regulatory Novartis announces MET inhibitor Tabrecta™ approved in Japan for advanced non-small cell lung cancer with METex14 novartis.com ↗ Tabrecta is approved for first-line and previously treated patients, regardless of prior treatment type.
2020-06-29	Incyte Corporation	Regulatory Incyte Announces Approval of Tabrecta™ (capmatinib) in Japan for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with METex14 incyte.com ↗ Incyte (Nasdaq: INCY) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved Tabrecta™ (capmatinib) for MET exon 14 skipping (METex14) mutation-positive advanced and/or recurrent unresectable non-small cell lung cancer (NSCLC).
2020-05-06	Novartis Pharmaceuticals	Regulatory Novartis announces FDA approval of MET inhibitor Tabrecta™ for metastatic non-small cell lung cancer with METex14 novartis.com ↗
2020-05-06	Incyte Corporation	Regulatory Incyte Announces FDA Approval of Tabrecta™ (capmatinib) for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with METex14 incyte.com ↗ Tabrecta is the first and only U.S. Food and Drug Administration (FDA)-approved treatment for adult patients with metastatic non-small cell lung cancer (NSCLC) with a mutation that leads to MET exon 14 skipping (METex14)
2020-02-11	Novartis Pharmaceuticals	Regulatory Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review novartis.com ↗ Novartis announced today that the US Food and Drug Administration (FDA) accepted and granted Priority Review to capmatinib’s (INC280) New Drug Application (NDA).
2020-02-11	Incyte Corporation	Regulatory Incyte Announces Acceptance and Priority Review of NDA for Capmatinib for Advanced Non-Small Cell Lung Cancer incyte.com ↗ Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the New Drug Application (NDA) for capmatinib, an investigational, selective MET inhibitor, as a treatment for first-line and previously treated patients with locally advanced or metastatic MET exon 14 skipping (METex14) mutated non-small cell lung cancer (NSCLC).
2019-09-06	Novartis Pharmaceuticals	Regulatory Novartis investigational lung cancer therapy capmatinib (INC280) granted FDA Breakthrough Therapy Designation for patients with MET-mutated advanced non-small cell lung cancer novartis.com ↗ The FDA granted Breakthrough Therapy Designation for capmatinib based on positive primary results
2019-06-03	Novartis Pharmaceuticals	Results Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials novartis.com ↗ Overall response rate among patients receiving capmatinib was 68% for treatment-naive and 41% for previously treated patients; median duration of response was also clinically meaningful irrespective of prior line of therapy
2019-06-03	Incyte Corporation	Results New Data from GEOMETRY mono-1 Study Show Clinically Meaningful Results in Patients with Non-Small Cell Lung Cancer with MET exon-14 Skipping Mutation Treated with Capmatinib incyte.com ↗ Incyte (Nasdaq:INCY) today announced primary efficacy results from the Novartis-sponsored GEOMETRY mono-1 Phase 2 clinical trial of capmatinib, an investigational, selective MET inhibitor.
2018-10-19	Novartis Pharmaceuticals	Results Novartis phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) shows positive results in patients with MET mutated advanced NSCLC novartis.com ↗ The GEOMETRY mono-1 study showed an overall response rate (ORR) of 72.0% (95% CI: 50.6-87.9) in treatment-naive patients and 39.1% (95% CI: 27.6-51.6) in previously treated patients.
2018-10-19	Incyte Corporation	Results Phase 2 GEOMETRY mono-1 Trial of Investigational Medicine Capmatinib Shows Positive Results in Patients with MET-mutated Advanced NSCLC incyte.com ↗ The GEOMETRY mono-1 study showed an overall response rate (ORR) of 72.0 percent (95% CI: 50.6-87.9) in treatment-naive patients and 39.1 percent (95% CI: 27.6-51.6) in previously treated patients.
2016-06-06	Novartis Pharmaceuticals	Results Novartis pivotal data for Tafinlar® + Mekinist® demonstrated a 63 percent overall response rate in treating rare form of lung cancer novartis.com ↗ The INC280 (capmatinib) data, from a Phase I, single agent study (NCT01324479) in patients with advanced cMET+ NSCLC and a Phase Ib/II combination study (NCT01610336) with gefitinib in patients with EGFR-mutated, cMET+ NSCLC, demonstrated encouraging early signs of clinical activity[4],[5].

All press releases naming this drug 24 releases

Date	Issuer	Release
2024-05-23	Janssen Research & Development, LLC	Johnson & Johnson advances leadership in oncology innovation with more than 75 clinical study and real-world presentations at ASCO and EHA jnj.com ↗
2023-05-26	Chugai Pharmaceutical	Chugai Obtains Approval for FoundationOne Liquid CDx Cancer Genomic Profile to Be Used as a Companion Diagnostic for Novartis’ MET Inhibitor, Capmatinib, Which Is Approved for MET Exon 14 Skipping Mutation-Positive Advanced and/or Recurrent Unresectable Non-Small Cell Lung Cancer chugai-pharm.co.jp ↗
2022-06-22	Novartis Pharmaceuticals	Novartis receives European Commission approval for Tabrecta® for the treatment of METex14 skipping advanced non-small cell lung cancer novartis.com ↗
2022-04-22	Novartis Pharmaceuticals	Novartis receives positive CHMP opinion for Tabrecta® for patients with METex14 advanced non-small cell lung cancer novartis.com ↗
2022-04-22	Incyte Corporation	Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta®) for the Treatment of METex14 Advanced Non-Small Cell Lung Cancer incyte.com ↗
2021-06-04	Novartis Pharmaceuticals	Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC novartis.com ↗
2020-09-02	Novartis Pharmaceuticals	Novartis announces NEJM publication of pivotal study of Tabrecta™ in patients with METex14 metastatic non-small cell lung cancer novartis.com ↗
2020-09-02	Incyte Corporation	Incyte Announces Pivotal GEOMETRY mono-1 Study Results of Capmatinib (Tabrecta™) in Patients with METex14 Metastatic Non-Small Cell Lung Cancer Published in NEJM incyte.com ↗
2020-06-29	Novartis Pharmaceuticals	Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options novartis.com ↗
2020-06-29	Novartis Pharmaceuticals	Novartis announces MET inhibitor Tabrecta™ approved in Japan for advanced non-small cell lung cancer with METex14 novartis.com ↗
2020-06-29	Incyte Corporation	Incyte Announces Approval of Tabrecta™ (capmatinib) in Japan for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with METex14 incyte.com ↗
2020-05-29	Chugai Pharmaceutical	Chugai Obtains Approval for Expanded Use of FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic of Novartis’ MET inhibitor, Capmatinib for Non-Small Cell Lung Cancer with MET exon 14 Skipping Alterations chugai-pharm.co.jp ↗
2020-05-06	Novartis Pharmaceuticals	Novartis announces FDA approval of MET inhibitor Tabrecta™ for metastatic non-small cell lung cancer with METex14 novartis.com ↗
2020-05-06	Incyte Corporation	Incyte Announces FDA Approval of Tabrecta™ (capmatinib) for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with METex14 incyte.com ↗
2020-02-11	Novartis Pharmaceuticals	Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review novartis.com ↗
2020-02-11	Incyte Corporation	Incyte Announces Acceptance and Priority Review of NDA for Capmatinib for Advanced Non-Small Cell Lung Cancer incyte.com ↗
2019-09-06	Novartis Pharmaceuticals	Novartis investigational lung cancer therapy capmatinib (INC280) granted FDA Breakthrough Therapy Designation for patients with MET-mutated advanced non-small cell lung cancer novartis.com ↗
2019-06-03	Novartis Pharmaceuticals	Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials novartis.com ↗
2019-06-03	Incyte Corporation	New Data from GEOMETRY mono-1 Study Show Clinically Meaningful Results in Patients with Non-Small Cell Lung Cancer with MET exon-14 Skipping Mutation Treated with Capmatinib incyte.com ↗
2018-10-19	Novartis Pharmaceuticals	Novartis phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) shows positive results in patients with MET mutated advanced NSCLC novartis.com ↗
2018-10-19	Incyte Corporation	Phase 2 GEOMETRY mono-1 Trial of Investigational Medicine Capmatinib Shows Positive Results in Patients with MET-mutated Advanced NSCLC incyte.com ↗
2016-06-06	Novartis Pharmaceuticals	Novartis pivotal data for Tafinlar® + Mekinist® demonstrated a 63 percent overall response rate in treating rare form of lung cancer novartis.com ↗
2016-05-19	Incyte Corporation	Incyte Highlights Jakafi® (ruxolitinib) and Capmatinib Abstracts to be Presented at the 2016 ASCO and EHA Annual Meetings incyte.com ↗
2013-04-29	Incyte Corporation	Incyte Achieves $25 Million Milestone as c-MET Inhibitor INC280 Advances Into Phase II Development incyte.com ↗

Evidence & citations 20 cited values

Every value below carries the sentence it was read from. 55 sources stand behind the page.

Field	Value	Cited text
Known as	capmatinib	“Pharmacokinetics and safety of capmatinib with food in patients with” PMID 34053700 ↗ May 2021 31 “INC280 (capmatinib)” PMID 31776899 ↗ Nov 2019 “Capmatinib” NCT04817956 ↗ NCT04816214 ↗ NCT05243641 ↗ NCT02414139 ↗ NCT04677595 ↗ NCT02335944 ↗ NCT04741789 ↗ NCT02587650 ↗ NCT03693339 ↗ Show 21 more sources
Known as	CAPMATINIB (INCB28060)	ChEMBL registry synonym — accepted as the source's own label CHEMBL3188267 ↗
Known as	Capmatinib dihydrochloride monohydrate	ChEMBL registry synonym — accepted as the source's own label CHEMBL3188267 ↗
Known as	CAPMATINIB HYDROCHLORIDE	ChEMBL registry synonym — accepted as the source's own label CHEMBL3188267 ↗
Known as	Capmatinib hydrochloride hydrate	ChEMBL registry synonym — accepted as the source's own label CHEMBL3188267 ↗
Known as	Capmatinib hydrochloride monohydrate	ChEMBL registry synonym — accepted as the source's own label CHEMBL3188267 ↗
Known as	INC280	“Capmatinib (INC280)” NCT02750215 ↗ 20 NCT02276027 ↗ NCT01964235 ↗ NCT01737827 ↗ NCT02468661 ↗ NCT03240393 ↗ NCT02323126 ↗ NCT01870726 ↗ NCT02205398 ↗ NCT02019693 ↗ NCT01546428 ↗ Show 10 more sources
Known as	INCB 28060	ChEMBL registry synonym — accepted as the source's own label CHEMBL3188267 ↗
Known as	INCB-28060 FREE BASE	ChEMBL registry synonym — accepted as the source's own label CHEMBL3188267 ↗
Known as	INCB-28060A-1419	ChEMBL registry synonym — accepted as the source's own label CHEMBL3188267 ↗
Known as	NVP-INC280	ChEMBL registry synonym — accepted as the source's own label CHEMBL3188267 ↗
Known as	NVP-INC280-AAA	ChEMBL registry synonym — accepted as the source's own label CHEMBL3188267 ↗
Known as	NVP-INC280-NX	ChEMBL registry synonym — accepted as the source's own label CHEMBL3188267 ↗
Known as	NYP-INC280-NX	ChEMBL registry synonym — accepted as the source's own label CHEMBL3188267 ↗
Known as	Rahika	“The Drugs Controller General of India (DCGI) granted approval for Rahika® (capmatinib) film-coated tablets (150 mg and 200 mg) for the treatment of adult patients with advanced...” NCT05110196 ↗
Known as	Tabrecta	ChEMBL registry synonym — accepted as the source's own label CHEMBL3188267 ↗
Action	Inhibit	“MET inhibitor” PMID 32240796 ↗ Mar 2020
Modality	Small molecule	— CHEMBL3188267 ↗
Route	Oral	“Capmatinib is an oral, ATP-competitive, and highly potent, type 1b MET inhibitor.” PMID 31778267 ↗ Dec 2019
Target	MET	“MET inhibitor” PMID 32240796 ↗ Mar 2020